Towards consensus practices to qualify safety biomarkers for use in early drug development

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Nature Biotechnology

• Publication date

  2010-05-01

• Fields of study

  Medicine, Computer Science

• Identifiers
  DOI 10.1038/nbt.1634PMID 20458314
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium

  2010cited by this paper
• Next-generation biomarkers for detecting kidney toxicity

  2010cited by this paper
• Kidney Injury Molecule-1 Outperforms Traditional Biomarkers of Kidney Injury in Multi-site Preclinical Biomarker Qualification Studies

  2010cited by this paper
• Urinary biomarkers trefoil factor 3 and albumin enable early detection of kidney tubular injury

  2010cited by this paper
• Research at the interface of industry, academia and regulatory science

  2010cited by this paper
• Urinary clusterin, cystatin C, β2-microglobulin and total protein as markers to detect drug-induced kidney injury

  2010cited by this paper
• A Prototypical Process for Creating Evidentiary Standards for Biomarkers and Diagnostics

  2008cited by this paper
• Strategic approach to fit-for-purpose biomarkers in drug development.

  2008cited by this paper
• Preclinical Predictors of Clinical Safety: Opportunities for Improvement

  2007cited by this paper
• Biomarkers and Surrogate End Points for Fit‐for‐Purpose Development and Regulatory Evaluation of New Drugs

  2007cited by this paper
• Biomarker Development, Commercialization, and Regulation: Individualization of Medicine Lost in Translation

  2007cited by this paper
• Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement

  2006cited by this paper
• Bias as a threat to the validity of cancer molecular-marker research

  2005cited by this paper
• Best Practices Guideline: Toxicologic Histopathology

  2004cited by this paper
• Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework

  2001cited by this paper
• Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis

  2001cited by this paper
• Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction.

  2000cited by this paper
• Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction.

  2000cited by this paper
• Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach.

  1988cited by this paper
• Cardiac-specific troponin-I radioimmunoassay in the diagnosis of acute myocardial infarction.

  1987cited by this paper
• The Environment and Disease: Association or Causation?

  1965cited by this paper

• Obesity Biomarkers: Exploring Factors, Ramification, Machine Learning, and AI‐Unveiling Insights in Health Research

  2025cites this paper
• Infliximab ameliorates vancomycin-triggered nephrotoxicity: Biochemical, molecular, and histopathological insights.

  2025cites this paper
• Enhancing therapeutic strategies and drug development for patients with kidney disease

  2025cites this paper
• Investigation of urinary miRNA profile changes in amphotericin B-induced nephrotoxicity in C57BL/6 mouse, Sprague–Dawley rats and Beagle dogs

  2025cites this paper
• Magnitude of Urine Albumin and KIM-1 Changes Can be Used to Differentiate Glomerular Injury From Tubular Injury in Rats

  2024cites this paper
• A Survey on Computational Methods in Drug Discovery for Neurodegenerative Diseases

  2024cites this paper
• Early-Onset albuminuria and Associated Renal Pathology in Leucine-Rich Repeat Kinase 2 Knockout Rats

  2023cites this paper
• Activated SOX9+ renal epithelial cells promote kidney repair through secreting factors

  2023cites this paper
• Toll-Like Receptor 4 Induction During Renal Ischemia Correlates with Serum Creatinine in a Pig Model

  2023cites this paper
• Evaluation of Renal Biomarkers, Including Symmetric Dimethylarginine, following Gentamicin-Induced Proximal Tubular Injury in the Rat

  2021cites this paper
• A Review of Specific Biomarkers of Chronic Renal Injury and Their Potential Application in Nonclinical Safety Assessment Studies

  2021cites this paper
• Machine Learning in Drug Discovery: A Review

  2021cites this paper
• ADVANCED PRECLINICAL MODELS FOR EVALUATION OF DRUG INDUCED LIVER INJURY - CONSENSUS STATEMENT BY THE EUROPEAN DRUG-INDUCED LIVER INJURY NETWORK [PRO-EURO-DILI-NET].

  2021cites this paper
• Urinary Metabolomics from a Dose-Fractionated Polymyxin B Rat Model of Acute Kidney Injury

  2021cites this paper
• Kidney Injury Monitoring in Tobramycin-Treated Rhesus Monkeys: Supplementing Urinary Kidney Biomarkers With Kidney Biopsy Gene Expression Profiling

  2021cites this paper
• Роль биомаркеров острого повреждения почек в прогнозировании функциональных результатов хирургического лечения у больных локализованным раком почки

  2021cites this paper
• Precision medicine

  2020cites this paper
• Urinary miRNA Biomarkers of Drug-Induced Kidney Injury and Their Site Specificity Within the Nephron

  2020cites this paper
• The Utility of Novel Urinary Biomarkers in Mice for Drug Development Studies

  2020cites this paper
• Evaluation of urinary biomarkers for early detection of acute kidney injury in a rat nephropathy model.

  2020cites this paper
• Evaluation of 10 Urinary Biomarkers for Renal Safety With 5 Nephrotoxicants in Nonhuman Primates

  2020cites this paper
• Evaluation of biomarkers for in vitro prediction of drug-induced nephrotoxicity in RPTEC/TERT1 cells.

  2020cites this paper
• Urine kidney safety biomarkers improve understanding of indirect intra-renal injury potential in dogs with a drug-induced prerenal azotemia.

  2020cites this paper
• Predictive Nephrotoxicity Profiling of a Novel Antifungal Small Molecule in Comparison to Amphotericin B and Voriconazole

  2020cites this paper
• Pharmacodynamic Markers of LRRK2 Inhibition in Biofluids

  2020cites this paper
• Evaluation of Dose-Fractionated Polymyxin B on Acute Kidney Injury Using a Translational In Vivo Rat Model

  2020cites this paper
• Lack of synergistic nephrotoxicity between vancomycin and piperacillin/tazobactam in a rat model and a confirmatory cellular model.

  2020cites this paper
• Safety in Early Phase Studies

  2019cites this paper
• Comparative Performance of Urinary Biomarkers for Vancomycin-Induced Kidney Injury According to Timeline of Injury

  2019cites this paper
• Research and development of anticancer agents under the guidance of biomarkers

  2019cites this paper
• Biomarkers of Acute and Chronic Kidney Disease.

  2019cites this paper
• Investigating the Value of Urine Volume, Creatinine, and Cystatin C for Urinary Biomarkers Normalization for Drug Development Studies

  2019cites this paper
• The significance of combined detection of CysC, urinary mAlb and β2-MG in diagnosis of the early renal injury in pregnancy-induced hypertension syndrome

  2019cites this paper
• Evaluation of Dose Fractionated Polymyxin B on Acute Kidney Injury: A Translational In Vivo Model

  2019cites this paper
• Changes in novel gastrointestinal and renal injury markers in the blood plasma of sheep following increasing intravenous doses of tolfenamic acid.

  2019cites this paper
• Urinary biomarker and histopathological evaluation of vancomycin and piperacillin-tazobactam nephrotoxicity in comparison with vancomycin in a rat model and a confirmatory cellular model

  2019cites this paper
• Predictive Markers of LRRK2 Inhibition in Biofluids

  2019cites this paper
• A Performance Evaluation of Liver and Skeletal Muscle-Specific miRNAs in Rat Plasma to Detect Drug-Induced Injury

  2018cites this paper
• An in vitro method for nephrotoxicity evaluation using HK-2 human kidney epithelial cells combined with biomarkers of nephrotoxicity.

  2018cites this paper
• A multi-center preclinical study of gadoxetate DCE-MRI in rats as a biomarker of drug induced inhibition of liver transporter function

  2018cites this paper
• Regulatory landscapes for biomarkers and diagnostic tests: Qualification, approval, and role in clinical practice

  2018cites this paper
• Performance Assessment of New Urinary Translational Safety Biomarkers of Drug-induced Renal Tubular Injury in Tenofovir-treated Cynomolgus Monkeys and Beagle Dogs

  2018cites this paper
• Polymer Therapeutics: Biomarkers and New Approaches for Personalized Cancer Treatment

  2018cites this paper
• Qualification of safety biomarkers for use in drug development: What has been achieved and what is the path forward?

  2017cites this paper
• A Multiplatform Approach for the Discovery of Novel Drug-Induced Kidney Injury Biomarkers.

  2017cites this paper
• Emerging Translatable Safety Biomarkers

  2017cites this paper
• The Role of Public–Private Partnerships in Catalyzing the Critical Path

  2017cites this paper
• Current practices and future outlook on the integration of biomarkers in the drug development process.

  2017cites this paper
• Salt Selection Matters: Differential Renal Toxicity With MDV1634.Maleate Versus MDV1634.2HCl

  2017cites this paper
• Evaluation of Vancomycin Exposures Associated with Elevations in Novel Urinary Biomarkers of Acute Kidney Injury in Vancomycin-Treated Rats

  2016cites this paper
• Promoting Adoption of the 3Rs through Regulatory Qualification.

  2016cites this paper
• Evaluation of KIM-1 and NGAL as Early Indicators for Assessment of Gentamycin-Induced Nephrotoxicity In Vivo and In Vitro

  2016cites this paper
• Medication-Induced Nephrotoxicity in Older Patients.

  2016cites this paper
• Translatable Biomarkers in Drug Development

  2016cites this paper
• Integrating biomarkers to predict renal and cardiovascular drug efficacy

  2016cites this paper
• The Predictive Safety Testing Consortium: safety bio-markers, collaboration, and qualification

  2016cites this paper
• Recent Successes in the Identification, Development, and Qualification of Translational Biomarkers

  2015cites this paper
• Personalized Medicine: A Review with Regard to Biomarkers

  2015cites this paper
• Regaining Health Technology Assessment from Oblivion: Improving and Integrating Regulation of Drugs, Medical Devices, Diagnostic Tests and Surgical Innovations

  2015cites this paper
• Biomarkers in Pharmaceutical Research.

  2015cites this paper
• The Actual Role of Receptors as Cancer Markers, Biochemical and Clinical Aspects: Receptors in Breast Cancer.

  2015cites this paper
• Evaluation of biomarkers for in vitro prediction of drug-induced nephrotoxicity: comparison of HK-2, immortalized human proximal tubule epithelial, and primary cultures of human proximal tubular cells

  2015cites this paper
• Biomarkers of tobacco smoke exposure.

  2014cites this paper
• The Use of Surrogate Endpoints in Regulating Medicines for Cardio-Renal Disease: Opinions of Stakeholders

  2014cites this paper
• Safety Biomarkers in Preclinical Development

  2014cites this paper
• The Predictive Safety Testing Consortium and the Coalition Against Major Diseases

  2014cites this paper
• Cell- and biomarker-based assays for predicting nephrotoxicity

  2014cites this paper
• Multi-stakeholder collaborations & biomarker development and implementation

  2014cites this paper
• Evaluation of the relative performance of 12 urinary biomarkers for renal safety across 22 rat sensitivity and specificity studies.

  2014cites this paper
• Evolving Global Regulatory Science Through the Voluntary Submission of Data: A 2013 Assessment

  2014cites this paper
• Comparison between Male and Female Sprague-Dawley Rats in the Response of Urinary Biomarkers to Injury Induced by Gentamicin

  2014cites this paper
• Identification and evaluation of the predictive and diagnostic value of biomarkers applied to multi organ deficiencies in Cystic Fibrosis

  2014cites this paper
• Biomarkers in pharmacology and drug discovery.

  2014cites this paper
• Assessment Standards

  2014cites this paper
• Detection of Experimental Cisplatin-induced Kidney Injury in Rats Assessment Standards : Comparing Histopathology , Digital Image Analysis , and Stereology for Early

  2014cites this paper
• Molecular markers of kidney injury.

  2013cites this paper
• Qualified kidney biomarkers and their potential significance in drug safety evaluation and prediction.

  2013cites this paper
• Introduction to Toxicologic Pathology

  2013cites this paper
• Opportunities and Challenges of Safety Biomarker Qualification: Perspectives from the Predictive Safety Testing Consortium

  2013cites this paper
• Mechanistic Evidence in Evidence-Based Medicine: A Conceptual Framework

  2013cites this paper
• Clinical Pathology in Non-Clinical Toxicology Testing

  2013cites this paper
• Biomarkers: Discovery, Qualification and Application

  2013cites this paper
• – Part of the Special Issue – Pharmacology in 21 st Century Biomedical Research Biomarkers in pharmacology and drug discovery

  2013cites this paper
• Qualification of Urinary Biomarkers for Kidney Toxicity

  2013cites this paper
• Frontiers in Preclinical Safety Biomarkers

  2013cites this paper
• The current status of biomarkers for predicting toxicity

  2013cites this paper
• Assessment of emerging biomarkers of liver injury in human subjects.

  2013cites this paper
• Chapter 47 – Kidney

  2013cites this paper
• Markers for nutrition studies: review of criteria for the evaluation of markers

  2013cites this paper
• Urinary Tubular Protein-Based Biomarkers in the Rodent Model of Cisplatin Nephrotoxicity

  2013cites this paper
• Biomarker panel of cardiac and skeletal muscle troponins, fatty acid binding protein 3 and myosin light chain 3 for the accurate diagnosis of cardiotoxicity and musculoskeletal toxicity in rats.

  2012cites this paper
• 3.10 – Issues and Pitfalls in Biomarker Development and Clinical Relevance

  2012cites this paper
• Nenatal drug induced nephrotoxicity : old and next generation biomarkers for early detection and management of neonatal drug-induced nephrotoxicity, with special emphasis on uNGAL and on metabolomics.

  2012cites this paper
• Repeated intravenous infusion of human apolipoprotein(a) kringle V is associated with reversible dose-dependent acute tubulointerstitial nephritis without affecting glomerular filtration function.

  2012cites this paper
• Pharmacovigilance in Europe: direction of travel in a changing environment

  2012cites this paper
• Is It Possible for FDA Regulatory Scientists and Industry Scientists to Work Together? 2011 William B. Abrams Lecture 4 May 2011 Silver Spring, Maryland

  2012cites this paper
• A performance evaluation of three drug-induced liver injury biomarkers in the rat: alpha-glutathione S-transferase, arginase 1, and 4-hydroxyphenyl-pyruvate dioxygenase.

  2012cites this paper
• Metabolomics data and the biomarker qualification process

  2012cites this paper
• Personalized medicine using DNA biomarkers: a review

  2012cites this paper
• Biomarkers in Acute and Chronic Kidney Diseases

  2012cites this paper